Clinical trials: Hepatic Cancer
Liver Diseases, Humans
Liver Disease and Other Systemic Diseases
Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing…
- Conditions
- Liver Diseases, Humans, Progression, Carcinogenesis
- Trial name
- NCT04525833
- Where
- Taiwan
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Lipid Profile
Hypoglycemic Potential of Garcinia Cambogia (Garcinia Gummi-gutta (L.) N.Robson) Rind Powder Among Pre-diebetic Obese Patients
Garcinia cambogia, rich in hydroxycitric acid (HCA), has been suggested to promote weight loss and improve metabolic parameters. Evidence regarding its efficacy in pre-diabetic obese adults remains limited.
- Trial name
- NCT07419074
- Testing
- Garcinia cambogia rind powder
- Where
- Pakistan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Lahore
Liver Neoplasm, HBV Infection
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma…
- Conditions
- Liver Neoplasm, HBV Infection, Non-alcoholic Fatty Liver Disease NAFLD, Liver Fibrosis
- Trial name
- NCT07265544
- Testing
- Collection of Preoperative Peripheral Blood, Collection of Discarded Liver Tissue During Surgery
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Hepatic resection is the most effective curative treatment for resectable HCC, whereas frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor survivals.
- Trial name
- NCT03914352
- Testing
- PD-1 antibody, TACE
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cancer Hospital of Guangxi Medical University
Neoplasms, Cancer
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys.
- Conditions
- Neoplasms, Cancer, Caregiver
- Trial name
- CER (NCT02333604)
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Cancer Support Community, Research and Training Institute, Philadelphia
Liver Cancer, Hepatocellular Carcinoma
Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC
Due to providing valuable clinical information while being minimally invasive, blood-based testing will most likely be a prerequisite for future large-scale screening of high-risk populations.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- NCT04221347
- Testing
- blood sampling
- Where
- Czechia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Military University Hospital, Prague
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Liver Cancer, Esophageal Cancer
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease…
- Conditions
- Liver Cancer, Esophageal Cancer, Colorectal Cancer, Lung Adenocarcinoma
- Trial name
- TEG (NCT05517811)
- Testing
- TEG indices
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Caregiver, Malignant Neoplasm
Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients
This phase I/II trial studies how well patient portal and navigation program work in providing information for Asian American cancer patients.
- Conditions
- Caregiver, Malignant Neoplasm, Physician, Stage I Colorectal Cancer AJCC v8
- Trial name
- NCT03867916
- Testing
- Patient Navigation Program, Quality-of-Life Assessment, Survey Administration
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma, Hepatitis B
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI
Hepatocellular carcinoma (HCC) has been the leading cause of cancer death in Taiwan. Though Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin(DCP) are used as the tumor markers for diagnosis of HCCs.
- Conditions
- Hepatocellular Carcinoma, Hepatitis B, Hepatitis C
- Trial name
- NCT00154531
- Where
- Taiwan
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection
There are limited treatment options for HCC with high recurrence risk, and there is no consistent plan for adjuvant therapy after surgery. Hence an unmet clinical need.
- Trial name
- NCT05546619
- Testing
- HIPEC+tislelizumab + targeted therapy
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sulai Liu
Hepatocellular Carcinoma
Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma
the purpose of this study is to evaluate the efficacy and safety of aptinib in patients with advanced HCC
- Trial name
- HCC (NCT03398122)
- Testing
- TACE, Apatinib
- Where
- China
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades. Approximately 70-80% of newly diagnosed HCC patients already have advanced disease.
- Trial name
- NCT04193696
- Testing
- Radiation therapy and systemic anti-PD-1 immunotherapy for patients with advanced hepatocellular carcinoma
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Hepatocellular Carcinoma
The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC
Egypt is an endemic area of HCV.Cirrhosis and HCC are the most serious complications of chronic HCV infection.Some studies noted that the risk of HCC increased 17-fold among HCV-infected patients compared with anti-HCV negative…
- Trial name
- NCT03722628
- Testing
- MMP1 genotypes polymorphism
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hepatocellular Carcinoma, Insulin Resistance
The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With Insulin Resistance
Exercise is predicted to have positive effect among patients with hepatocellular carcinoma (HCC). However, little attention has been paid to the role of physical activity with wearable device in the management of HCC patients in…
- Trial name
- NCT04649671
- Testing
- Mobile health
- Where
- South Korea
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
This study aims to compare the effect of antiviral therapy with entecavir or tenofovir for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Included patients will randomly divide into two groups.
- Trial name
- NCT02650271
- Testing
- Entecavir, Tenofovir
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Liver Metastases
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or…
- Trial name
- HITM-SURE (NCT02850536)
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Roger Williams Medical Center
Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment
This is a Phase I, single-center, open-label, parallel-group study. A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic…
- Trial name
- NCT07550634
- Testing
- MDR-001
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Healthy
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
The study aims to assess the pharmacokinetics and safety of DPH001, an amorphous formulation of sorafenib, compared to Nexavar® in healthy volunteers.
- Trial name
- NCT06797427
- Testing
- DPH001, Nexavar (Sorafenib)
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Disruptive Pharma